Industry Overview - The Zacks Tobacco industry is facing significant challenges due to persistent pressure on cigarette volumes, driven by inflation, changing consumer preferences, and stringent regulations [1][4] - Traditional cigarette consumption is declining due to rising health awareness and tighter restrictions on tobacco sales and marketing [1][4] - The industry includes companies that manufacture cigarettes and various tobacco and nicotine-based products, with many firms also producing reduced-risk products (RRPs) like e-cigarettes and heated tobacco [3] Current Trends - Persistent pressure on cigarette volumes is attributed to inflation and economic factors that have altered consumer spending behavior, alongside regulatory restrictions impacting sales [4] - Elevated costs from global inflation affecting key inputs such as tobacco leaf, energy, and labor are adding to margin pressures, despite companies attempting to offset these through pricing actions [5] - The rising popularity of smoke-free options, including heated tobacco and vapor products, is reshaping the industry, with major companies investing in these categories to align with consumer preferences [6] Company Performance - Leading companies like Philip Morris International, British American Tobacco, and Altria Group are focusing on smoke-free alternatives to demonstrate resilience in a challenging environment [2] - Philip Morris is recognized for its transformative shift towards smoke-free products, with flagship offerings like IQOS and ZYN gaining traction [17] - British American Tobacco is advancing its transition through a diversified strategy, with brands like Vuse and glo gaining market share [21] - Altria is evolving its business model by prioritizing reduced-risk products and leveraging its strong brand portfolio, including Marlboro [25] Financial Metrics - The Zacks Tobacco industry currently holds a Zacks Industry Rank of 218, placing it in the bottom 10% of over 243 Zacks industries, indicating dull near-term prospects [7][8] - The industry has gained 16.1% over the past year, underperforming the S&P 500's growth of 18.7% but outperforming the broader Zacks Consumer Staples sector, which declined by 4.4% [10] - The industry is trading at a forward 12-month price-to-earnings (P/E) ratio of 14.61X, compared to the S&P 500's 20.8X and the sector's 16.39X [13] Earnings Estimates - The Zacks Consensus Estimate for Philip Morris's 2026 and 2027 earnings per share (EPS) remains unchanged at $8.49 and $9.30, respectively [18] - For British American Tobacco, the EPS estimates for 2026 and 2027 have decreased slightly to $4.87 and $5.29, respectively [22] - Altria's EPS estimates for 2026 and 2027 remain unchanged at $5.61 and $5.78, respectively [26]

Core Insights - Altria Group, Inc. is focusing on its smoke-free strategy, particularly through its oral nicotine portfolio, which has shown significant growth, with nicotine pouches driving a 14% volume increase over the past six months [1][8] Oral Nicotine Market Performance - By Q4 2025, oral nicotine pouches represented nearly 57% of the total oral category, gaining 10.4 share points year over year, indicating a rapid consumer shift within oral tobacco [2] - Altria's flagship pouch brand, on!, demonstrated resilience amid competitive pricing pressures, with a 3% price increase while the broader category saw a 12% decline in pricing [3] - For the full year 2025, on! shipment volumes increased by 10.9% to over 177 million cans, maintaining an 8.2% retail share of the total oral tobacco category, up 0.1 share point from the previous year [3][8] Future Growth Potential - The momentum for Altria's oral nicotine products is expected to strengthen further in 2026 with the national launch of on! PLUS, a premium pouch that has received FDA marketing authorization for three varieties, targeting high-velocity segments [4] Competitive Landscape - Philip Morris International Inc. reported net revenues of $16.9 billion from its smoke-free segment in 2025, contributing 41.5% to total revenues, driven by the global expansion of IQOS and increased U.S. ZYN shipments [5] - Turning Point Brands, Inc. experienced a remarkable 627.6% year-over-year increase in its Modern Oral segment, with white nicotine pouches accounting for 30.8% of total business by the end of Q3 2025 [6] Valuation and Estimates - Altria's shares have increased by 10.9% in the past month, outperforming the industry growth of 5% [7] - The company trades at a forward price-to-earnings ratio of 12.32X, lower than the industry average of 16.2X [9] - The Zacks Consensus Estimate for Altria's earnings per share for 2026 is $5.57, with a slight decrease of 1 cent, while the estimate for 2027 has increased by 5 cents to $5.76 [10]

Core Insights - Altria Group, Inc. and Philip Morris International Inc. are leading companies in the global tobacco industry, focusing on cigarette and nicotine product sales amid changing consumer preferences [1][2] - Altria has a market capitalization of approximately $116.6 billion, while Philip Morris has a larger market value of around $291.9 billion, reflecting its international presence and leadership in next-generation products [1][2] Altria Group, Inc. Overview - Altria's investment appeal is supported by resilient cash-flow generation and consistent shareholder returns, with a 4.4% adjusted EPS growth in 2025 and approximately $8 billion returned to shareholders through dividends and share repurchases [3][4] - The smokeable products segment generated over $11 billion in adjusted operating income in 2025, with margins expanding to 63.4% due to strong pricing execution [4] - Altria is advancing its smoke-free portfolio, particularly in modern oral nicotine, with a 10.9% shipment volume growth for the on! brand in 2025 [5] - Domestic cigarette volumes declined approximately 9.5% in 2025, indicating ongoing pressure in the combustible category [6] Philip Morris International Inc. Overview - Philip Morris demonstrated a strong growth profile in 2025 with a 14.8% adjusted EPS growth, net revenues exceeding $40 billion, and organic operating income growth of 10.6% [7][8] - Smoke-free products accounted for 41.5% of total net revenues and nearly 43% of gross profit in 2025, with IQOS heated tobacco units and ZYN nicotine pouches showing significant growth [9][10] - Despite a 1.5% decline in combustible cigarette shipments, pricing actions helped lift combustible net revenues by 2.5% [10] - Management projects 2026 adjusted EPS growth of 11.1% to 13.1%, indicating confidence in the company's operating momentum [11] Comparative Analysis - Altria's shares increased by 26.1% over the past year, outperforming Philip Morris's 21.7% gain, although both lagged behind the industry growth of 33.8% [12] - Altria trades at a forward P/E ratio of 12.4, while Philip Morris trades at a forward P/E of 21.82, indicating differing valuations [16] - Philip Morris is viewed as the stronger growth story due to its accelerated shift toward smoke-free products and global scale, while Altria is seen as a stable income choice reliant on its U.S. combustible franchise [17]

Core Insights - Altria Group, Inc. demonstrated resilience in its fourth-quarter 2025 performance, maintaining earnings growth despite ongoing cigarette volume declines and regulatory challenges [1][9] - The company has effectively utilized pricing power, disciplined cost management, and strategic investments in smoke-free alternatives to protect margins [1][21] Stock Performance - Following the fourth-quarter results released on January 29, 2026, Altria's shares increased by 12%, indicating improved investor confidence in its earnings stability [2] - Over the past three months, Altria's shares rose by 15.9%, outperforming the Zacks Consumer Staples sector's 12.1% and the S&P 500's 3.7% [3] - Compared to peers, Altria's performance was solid, with notable gains from Turning Point Brands (31.9%), Philip Morris (21.8%), and British American Tobacco (11.3%) [4] Financial Results - Altria's fourth-quarter adjusted earnings remained flat year-over-year at $1.30, with net revenues declining by 2.1% to $5.8 billion, primarily due to lower revenues in the smokeable products segment [9][10] - Domestic cigarette shipment volumes fell by 7.9% in the quarter, contributing to revenue pressures, but adjusted operating companies income (OCI) remained resilient at $2.64 billion with margins at 60.4% [11] - The Oral Tobacco Products segment also contributed positively, with adjusted OCI declining slightly to $440 million but showing growth in the modern oral portfolio [12] Capital Returns - Altria paid $7 billion in dividends in 2025, including $1.8 billion in the fourth quarter, showcasing strong cash generation capabilities [13] - The company repurchased 4.8 million shares for $288 million in the fourth quarter, with a total of 17.1 million shares repurchased for approximately $1 billion in the full year [14] 2026 Outlook - Management expects 2026 adjusted EPS in the range of $5.56 to $5.72, indicating growth of 2.5% to 5.5% from 2025 [15] - The outlook is based on anticipated pricing strength, cost discipline, and planned investments in smoke-free products, with capital expenditures projected between $300 million and $375 million [16] Valuation - Altria is currently trading at a forward P/E ratio of 11.98X, significantly lower than the industry average of 16.07X and the S&P 500's average of 22.9X, making it attractive for value-focused investors [17] - Compared to peers, Altria's valuation is appealing, as Philip Morris and Turning Point Brands trade at higher multiples of 22.39X and 31.65X, respectively [18] Investor Sentiment - The post-earnings rally reflects growing recognition of Altria's consistent execution, resilient margins, and dependable cash-return framework [21] - Despite ongoing structural challenges, the company's ability to offset pressures through pricing and cost management enhances its appeal for long-term, income-oriented investors [21]

Core Insights - The tobacco sector is primarily represented by two industry leaders: Altria Group, Inc. and Philip Morris International Inc., each with distinct geographic focuses and strategies to adapt to the evolving nicotine landscape [1][2] Altria Group, Inc. (MO) - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into smoke-free alternatives like NJOY and oral nicotine products [2] - In 2025, Altria achieved a 4.4% increase in adjusted earnings per share and returned approximately $8 billion to shareholders through dividends and share repurchases, highlighting its strong cash-flow generation [3] - The smokeable products segment generated over $11 billion in adjusted operating income with margins expanding to 63.4%, demonstrating Altria's pricing power despite a 9.5% decline in domestic cigarette volumes [4][6] - Altria's smoke-free strategy is advancing, with on! brand shipment volumes rising 10.9% in 2025, and plans for a national rollout of on! PLUS to capture growth in the nicotine pouch category [5] - The long-term investment outlook for Altria is challenged by structural and regulatory headwinds, with ongoing volume declines in traditional cigarettes [6] Philip Morris International Inc. (PM) - Philip Morris is transitioning towards smoke-free products, with smoke-free offerings accounting for 41% of total net revenues and 42% of gross profit in Q3 2025, driven by strong performance from IQOS, ZYN, and VEEV [7][8] - The company reported a record quarterly smoke-free gross profit of $3.1 billion, indicating a shift towards a more sustainable profit model [7] - Philip Morris' operational discipline and productivity initiatives have supported margin expansion and earnings growth, despite a 3.2% decline in cigarette shipment volumes in Q3 [10][11] - The reliance on smoke-free products introduces risks, as any slowdown in adoption could impact the ability to offset declines in combustible product volumes [11] Stock Performance and Valuation - Over the past year, Altria's shares increased by 15.9%, underperforming Philip Morris, which surged by 36.5%, and the industry's growth of 38.7% [12] - Altria's forward P/E ratio is 10.7, slightly below its one-year median, while Philip Morris' forward P/E ratio stands at 21.12, above its median [13] - Philip Morris is viewed as a more promising investment due to its diversified international presence and established portfolio of reduced-risk products, while Altria's growth is limited by its heavy exposure to the U.S. cigarette market [16][17]

Core Insights - Altria Group's stock price fell over 5% following significant market share losses in the cigarette sector [1] Market Performance - Altria's domestic cigarette shipment volumes decreased by 7.9% in Q4, reflecting a continued decline in smoking rates in the U.S. [2] - The retail market share of Altria's Marlboro brand dropped to 39.8%, a year-over-year decline of 1.5 percentage points [2] Product Segments - Altria's oral tobacco products also experienced a decline, with shipment volumes falling by 6.3% due to market share losses [3] - The on! brand's share in the nicotine pouch category decreased by 5.3 percentage points to 13.4% [3] Financial Performance - Altria's revenues, net of excise taxes, slightly declined by less than 1% to $5.1 billion, with price increases offsetting lower shipment volumes [4] - Adjusted earnings per share remained flat at $1.30, supported by stock buybacks [4] - Management projects a growth in full-year adjusted earnings of 2.5% to 5.5% in 2026, estimating a range of $5.56 to $5.72 per share, aided by cost-cutting measures [4]

Financial Data and Key Metrics Changes - In 2025, adjusted diluted earnings per share grew by 4.4% and the company returned $8 billion to shareholders through dividends and share repurchases combined [4][24] - The smokable product segment delivered over $11 billion in adjusted operating income (OCI) for the full year, expanding adjusted OCI margins by 1.8 percentage points to 63.4% [16] - For the fourth quarter, adjusted OCI declined by 2.4%, and adjusted OCI margins contracted by 0.8 percentage points to 60.4% [16] Business Line Data and Key Metrics Changes - Domestic cigarette volumes declined by 7.9% in the fourth quarter and 10% for the full year [16] - The oral tobacco product segment retail share was 29.6% for the fourth quarter and 31.9% for the full year [21] - Total segment reported shipment volume decreased 6.3% for the fourth quarter and 5.5% for the full year [21] Market Data and Key Metrics Changes - The estimated number of adult consumers in the e-vapor and oral tobacco categories grew to almost 30 million, reflecting the potential for tobacco harm reduction in the U.S. [6] - The e-vapor category grew approximately 15% in 2025, with illicit products representing approximately 70% of the category [7][8] - The nicotine pouch category grew an estimated 14% over the past six months, with oral nicotine pouches now representing nearly 57% of the total oral category [9] Company Strategy and Development Direction - The company is focused on advancing its smoke-free portfolio and building new pathways for long-term growth in international modern oral and non-nicotine innovations [15] - Strategic investments in retail merchandising and product innovation are planned to support the national launch of on! PLUS in 2026 [12] - The company intends to maintain a measured approach to investments in e-vapor until the regulatory framework is functioning effectively [9] Management's Comments on Operating Environment and Future Outlook - Management noted that the primary driver of industry and smoke-free growth continues to be the widespread availability of illicit flavored, disposable e-vapor products [6] - The company expects to deliver 2026 full year adjusted diluted EPS in a range of $5.56-$5.72, representing a growth rate of 2.5%-5.5% from a $5.42 base in 2025 [14] - Management expressed confidence in the company's strategy and the opportunities ahead, emphasizing the importance of responsible participation in the e-vapor category [15] Other Important Information - The company recorded non-cash impairment charges of $1.3 billion related to e-vapor definite-lived intangible assets and goodwill [22] - The company paid $7 billion in dividends in 2025, marking its 60th increase in the last 56 years [24] Q&A Session Summary Question: Can you provide any color on the scope of the import/export program? - Management indicated that the program involves both upfront investments and the opportunity for duty drawback, setting up manufacturing capabilities for international markets [31] Question: Is the elevated CapEx associated with the investments for import/export a one-time increase? - Management confirmed that the primary driver of the increase is the investments for the import/export business, but they are not guiding for future CapEx [33] Question: How is the promotional strategy behind Basic affecting net price realization? - Management clarified that the strategy around Basic is independent of the duty drawback and is aimed at capturing consumers under economic pressure [40] Question: Are there any signs of increased smoking incidence among younger legal-aged nicotine users? - Management stated that there are no trends indicating increased smoking incidence among younger cohorts, emphasizing the need for expedited product authorizations [50] Question: What is the pricing strategy for on! PLUS? - Management believes on! PLUS is a differentiated product that commands a premium in the marketplace, with various introductory price promotions planned [51]

Altria's Fourth-Quarter and Full-Year 2025 Earnings Conference Call January 29, 2026 1 | ALCS | Q4 2025 | 1.29.26 | For Investor Purposes ONLY Safe Harbor Statement Statements, including earnings guidance, in this presentation that are not reported financial results or other historical information are "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current plans, estimates and expectations, and are not guarante ...

Core Insights - Altria Group, Inc. is shifting its business focus towards smoke-free products to counteract declining combustible volumes, with significant progress noted in the third quarter of 2025, particularly in oral nicotine and heated tobacco segments [2][5] Smoke-Free Product Performance - The on! nicotine pouch brand maintained a stable retail market share of 8.7% in Q3 2025, with year-to-date shipment volumes increasing by 14.8% to 133.6 million cans, indicating strong performance in a competitive market [3][9] - Altria has launched on! PLUS in select U.S. markets, targeting both existing smokeless users and consumers switching from other brands, which is seen as a strategic move to enhance its oral nicotine portfolio [4][9] Regulatory Developments - Altria has reached a significant regulatory milestone by filing a combined premarket tobacco product application and modified risk tobacco product application with the FDA for the Ploom device and Marlboro heated tobacco sticks, marking a crucial step in introducing Ploom to American consumers [5] Competitive Landscape - Philip Morris International Inc. reported a 16.6% increase in smoke-free shipment volumes in Q3 2025, with smoke-free products now constituting 41% of its total net revenues, showcasing strong growth in this sector [6] - Turning Point Brands, Inc. experienced a remarkable 627.6% year-over-year increase in Modern Oral sales, which accounted for 30.8% of its total business, reflecting the growing importance of oral nicotine in its smoke-free strategy [7] Financial Performance and Valuation - Altria's shares have increased by 8.3% over the past month, slightly underperforming the industry growth of 9.2% [8] - The company trades at a forward price-to-earnings ratio of 11.09X, which is lower than the industry average of 15.3X, indicating potential value [10] - The Zacks Consensus Estimate projects year-over-year earnings growth of 6.3% for the current financial year and 2.3% for the next [11]

Core Insights - Altria Group, Inc. is adjusting its growth strategy in response to declining cigarette demand, focusing on a diversified smoke-free portfolio to stabilize growth over time [1][4] Group 1: Altria's Strategy and Performance - Domestic cigarette shipment volumes for Altria fell by 8.2% in Q3 2025, influenced by the rise of flavored disposable e-vapor products and tighter consumer spending [1][8] - Altria is emphasizing a diversified smoke-free portfolio that includes oral nicotine, e-vapor, and heated tobacco to adapt to changing consumer preferences [1][4] - The oral nicotine segment is showing the strongest progress, with Altria's nicotine pouch brand, on!, holding an 8.7% retail share of the total oral tobacco category in the first nine months of 2025 [2] - Altria launched on! PLUS, a premium nicotine pouch aimed at traditional smokeless tobacco users and competing pouch consumers [2][8] - The company is facing challenges in the e-vapor market as it integrates NJOY, while also advancing its heated tobacco efforts through the Horizon joint venture [3][4] Group 2: Competitive Landscape - Philip Morris International Inc. is also shifting towards smoke-free products, with these products accounting for approximately 41% of its net revenues in Q3 2025, and shipment volumes increasing by 16.6% year over year [5] - Turning Point Brands, Inc. reported a significant increase in Modern Oral sales, which surged by 627.6% year over year to $36.7 million, representing about 30.8% of total net sales [6] Group 3: Financial Metrics and Estimates - Altria's shares have gained 0.6% over the past month, compared to the industry's growth of 5.2% [7] - The forward price-to-earnings ratio for Altria is 10.3X, lower than the industry's average of 14.35X [9] - The Zacks Consensus Estimate for Altria's earnings implies year-over-year growth of 6.3% for 2025 and 2.3% for 2026 [10]